Next 10 |
home / stock / me / me articles
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmac...
U.S. stocks traded mostly lower toward the end of trading, with the NASDAQ Composite falling around 0.5% on Thursday. The Dow traded down 0.01% to ...
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.64% to 37,996.39 while ...
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results. The comp...
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer a...
Shares of Intuitive Machines, Inc. (NASDAQ: LUNR) fell sharply in today’s pre-market trading. Intuitive Machines revealed Friday that its l...
Marco Troper, the 19-year-old UC Berkeley freshman and son of former YouTube CEO Susan Wojcicki, was found unresponsive in his college dorm this pa...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 30 points on Thursday. The Dow traded down 0.01% to 38...
Shares of Compass Minerals International, Inc. (NYSE: CMP) fell sharply during Thursday’s session following downbeat results. Compass Minera...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading preventive health and therapeutics company, and Nightingale Health Plc, a pioneer in biomarker testing and risk prediction, today announced a strategic collaboration to pilot Nightingale Hea...
SOUTH SAN FRANCISCO, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, today released a new genetic Bipolar Disorder report (Powered by 23andMe Research) for 23andMe+ Premium members, informing them if they are at h...
2024-06-04 12:48:12 ET Genetic database builder 23andMe (NASDAQ: ME) stock slid 10% through 12:05 p.m. ET Tuesday. Curiously, though, the news that 23andMe reported today seemed generally of the "good" variety. The company announced a collaboration with the nonprofit Colorectal ...